Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.76 |
| ▸ | DRD4 | P21917 | 8/20 | 0.76 |
| ▸ | DRD3 | P35462 | 7/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL7532474 | 0.93 | DRD2 (0.67) | DRD2DRD4DRD3CYP2D6KDM4E | |
| SCHEMBL7518794 | 0.88 | DRD4 (0.78) | DRD2DRD4DRD3CYP2D6KDM4E | |
| SCHEMBL7527827 | 0.86 | DRD2 (1.00) | DRD2DRD4DRD3CYP2D6KDM4E | |
| SCHEMBL7527501 | 0.86 | DRD4 (0.71) | DRD2DRD4DRD3CYP2D6KDM4E | |
| Hydrochloric Acid SCHEMBL7525468 | 0.85 | DRD4 (0.74) | DRD2DRD4DRD3CYP2D6KDM4E | |
| SCHEMBL7531148 | 0.84 | DRD2 (0.55) | DRD2DRD4DRD3CYP2D6KDM4E | |
| Oxalic Acid SCHEMBL7528961 | 0.81 | DRD4 (0.68) | DRD2DRD4DRD3CYP2D6KDM4E | |
| SCHEMBL6029911 | 0.81 | ALDH1A1 (0.67) | DRD2DRD4DRD3KDM4EMEN1 | |
| SCHEMBL7517306 | 0.81 | DRD2 (0.67) | DRD2DRD4DRD3CYP2D6KDM4E | |
| Oxalic Acid SCHEMBL7523502 | 0.80 | DRD2 (0.86) | DRD2DRD4DRD3CYP2D6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020099056-A1 | 6-(4-arylalkylpiperazin-1-yl) benzodioxane and 6-(4-arylalkypiperazin-1-yl) chromane derivatives: dopamine receptor subtype specific ligands | NEUROGEN CORPORATION | 2002-07-25 | — | — | US | claimed |
| US-6333329-B2 | USEFUL FOR TREATMENT AND/OR PREVENTION OF NEUROPSYCHOLOGICAL DISORDERS INCLUDING SCHIZOPHRENIA, MANIA, DEMENTIA, DEPRESSION, ANXIETY, COMPULSIVE BEHAVIOR, DRUG ABUSE, PARKINSON-LIKE MOTOR DISORDERS AND MOTION DISORDERS | NEUROGEN CORPORATION | 2001-12-25 | — | — | US | claimed |
| US-20010005753-A1 | 6-(4-arylalkylpiperazin-1-yl) benzodioxane and 6-(4-arylalkylpiperazin-1-yl) chromane derivatives: dopamine receptor subtype specific ligands | NEUROGEN CORPORATION | 2001-06-28 | — | — | US | claimed |
| EP-1091949-A2 | 6-(4-ARYLALKYLPIPERAZIN-1-YL)BENZODIOXANE AND 6-(4-ARYLALKYLPIPERAZIN-1-YL)CHROMANE DERIVATIVES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 2001-04-18 | — | — | EP | claimed |
| US-6177566-B1 | TREATMENT AND/OR PREVENTION OF NEUROPSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2001-01-23 | — | — | US | claimed |
| WO-2000000489-A2 | 6-(4-ARYLALKYLPIPERAZIN-1-YL)BENZODIOXANE AND 6-(4-ARYLALKYLPIPERAZIN-1-YL)CHROMANE DERIVATIVES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 2000-01-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010005753-A1 | 6-(4-arylalkylpiperazin-1-yl) benzodioxane and 6-(4-arylalkylpiperazin-1-yl) chromane derivatives: dopamine receptor subtype specific ligands | CHRNA6, HTR2C, HTR3C | DRD2 9/4885DRD4 28/4885DRD3 22/4885 |
| US-20020099056-A1 | 6-(4-arylalkylpiperazin-1-yl) benzodioxane and 6-(4-arylalkypiperazin-1-yl) chromane derivatives: dopamine receptor subtype specific ligands | CHRNA6, HTR3C, HTR2C | DRD2 7/4885DRD4 28/4885DRD3 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.